Academic Journal

GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer's disease mouse model.

Bibliographic Details
Title: GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer's disease mouse model.
Authors: Park, Hyunhee1 (AUTHOR), Kwon, Hyuk Sung1 (AUTHOR), Lee, Kyu-Yong1 (AUTHOR), Kim, Ye Eun1 (AUTHOR), Son, Jeong-Woo1 (AUTHOR), Choi, Na-Young1 (AUTHOR), Lee, Eun Ji1 (AUTHOR), Han, Myung-Hoon2 (AUTHOR), Park, Dong Woo3 (AUTHOR), Kim, Sangjae1,4 (AUTHOR) chiron@gemvax.com, Koh, Seong-Ho1,5 (AUTHOR) ksh213@hanyang.ac.kr
Superior Title: Brain, Behavior & Immunity. Jan2024, Vol. 115, p295-307. 13p.
Subject Terms: *LUTEINIZING hormone releasing hormone receptors, *ALZHEIMER'S disease, *GONADOTROPIN releasing hormone, *CYCLIC adenylic acid, *LABORATORY mice
Abstract: • GV1001 improved memory and cognition in both young and old 3xTg-AD mice. • GV1001 reduced the levels of Aβ oligomers and phosphorylated tau. • GV1001 reduced neuroinflammation by shifting phenotype of microglial and astrocyte. • GV1001 bound to gonadotropin-releasing hormone receptors. • Intracellular cAMP level increased after treatment with GV1001. GV1001 protects neural cells from amyloid-β (Aβ) toxicity and other stressors in in vitro studies and demonstrates clinically beneficial effects in patients with moderate to severe Alzheimer's disease (AD). Here, we investigated the protective effects and mechanism of action of GV1001 in triple transgenic AD (3xTg-AD) mice. We found that GV1001 improved memory and cognition in middle- and old-aged 3xTg-AD mice. Additionally, it reduced Aβ oligomer and phospho-tau (Ser202 and Thr205) levels in the brain, and mitigated neuroinflammation by promoting a neuroprotective microglial and astrocyte phenotype while diminishing the neurotoxic ones. In vitro , GV1001 bound to gonadotropin releasing hormone receptors (GnRHRs) with high affinity. Levels of cyclic adenosine monophosphate, a direct downstream effector of activated GnRHRs, increased after GV1001 treatment. Furthermore, inhibition of GnRHRs blocked GV1001-induced effects. Thus, GV1001 might improve cognitive and memory functions of 3xTg-AD mice by suppressing neuroinflammation and reducing Aβ oligomers levels and phospho-tau by activating GnRHRs and their downstream signaling pathways. [ABSTRACT FROM AUTHOR]
Copyright of Brain, Behavior & Immunity is the property of Academic Press Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Premier
Description
Description not available.